Search

Your search keyword '"Schouten, Harry C."' showing total 14 results
Start Over Author "Schouten, Harry C." Journal journal of clinical oncology
14 results on '"Schouten, Harry C."'

1. Impact of Three Courses of Intensified CHOP Prior to High-Dose Sequential Therapy Followed by Autologous Stem-Cell Transplantation As First-Line Treatment in Poor-Risk, Aggressive Non-Hodgkinʼs Lymphoma: Comparative Analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40

Author

van Imhoff, Gustaaf W., van der Holt, Bronno, MacKenzie, Marius A., vanʼt Veer, Mars B., Wijermans, Pierre W., Ossenkoppele, Gerrit J., Schouten, Harry C., Sonneveld, Pieter, Steijaert, Monique M.C., Kluin, Philip M., Kluin-Nelemans, Hanneke C., and Verdonck, Leo F.

Published
2005
Full Text
View/download PDF

4. Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.

Author

Harrison, Claire N., primary, Schaap, Nicolaas, additional, Vannucchi, Alessandro M, additional, Kiladjian, Jean-Jacques, additional, Jourdan, Eric, additional, Silver, Richard T., additional, Schouten, Harry C., additional, Passamonti, Francesco, additional, Zweegman, Sonja, additional, Talpaz, Moshe, additional, Verstovsek, Srdan, additional, Gerike, Torsten, additional, Rose, Shelonitda, additional, Li, Mingyu, additional, Brownstein, Carrie, additional, and Mesa, Ruben A., additional

Published
2019
Full Text
View/download PDF

5. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

Author

Emanuel, Robyn M, Dueck, Amylou C, Geyer, Holly L, Kiladjian, Jean-Jacques, Slot, Stefanie, Zweegman, Sonja, Te Boekhorst, Peter A W, Commandeur, Suzan, Schouten, Harry C, Sackmann, Federico, Kerguelen Fuentes, Ana, Hernández-Maraver, Dolores, Pahl, Heike L, Griesshammer, Martin, Stegelmann, Frank, Doehner, Konstanze, Lehmann, Thomas, Bonatz, Karin, Reiter, Andreas, Boyer, Francoise, Etienne, Gabriel, Ianotto, Jean-Christophe, Ranta, Dana, Roy, Lydia, Cahn, Jean-Yves, Harrison, Claire N, Radia, Deepti, Muxi, Pablo, Maldonado, Norman, Besses, Carlos, Cervantes, Francisco, Johansson, Peter L, Barbui, Tiziano, Barosi, Giovanni, Vannucchi, Alessandro M, Passamonti, Francesco, Andreasson, Bjorn, Ferrari, Maria L, Ferarri, Maria L, Rambaldi, Alessandro, Samuelsson, Jan, Birgegard, Gunnar, Tefferi, Ayalew, Mesa, Ruben A, Interne Geneeskunde, RS: GROW - School for Oncology and Reproduction, Service d'hématologie clinique [Avicenne], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Paleontology section, Transvaal Museum, Département d'Hématologie, Institut de Cancéro-hématologie, Hôpital Morvan [Brest], Service d'Hematologie et Médecine Interne, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Hematology, Ospedali Riuniti, Department of Oncology and Hematology, Università degli Studi di Modena e Reggio Emilia (UNIMORE), Department of Haematology, Division of Medicine, Institution for Medical Sciences, University Hospital, and CCA - Innovative therapy

Subjects
Male, Cancer Research, Disease, Severity of Illness Index, 0302 clinical medicine, fluids and secretions, MESH: Aged, 80 and over, Quality of life, Weight loss, Sickness Impact Profile, Surveys and Questionnaires, Prospective Studies, Young adult, Prospective cohort study, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, food and beverages, ORIGINAL REPORTS, Middle Aged, 3. Good health, MESH: Sickness Impact Profile, Oncology, MESH: Young Adult, 030220 oncology & carcinogenesis, Female, medicine.symptom, MESH: Myeloproliferative Disorders, Adult, medicine.medical_specialty, myelofibrosis, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Young Adult, Internal medicine, MESH: Severity of Illness Index, Severity of illness, medicine, otorhinolaryngologic diseases, Humans, Bone pain, Myeloproliferative neoplasm, Aged, Myeloproliferative Disorders, MESH: Humans, business.industry, MESH: Questionnaires, MESH: Quality of Life, MESH: Adult, medicine.disease, equipment and supplies, bacterial infections and mycoses, MESH: Male, MESH: Prospective Studies, Surgery, carbohydrates (lipids), Quality of Life, business, MESH: Female, 030215 immunology
Abstract

Purpose Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development of MPN-directed therapies. We aimed to assess the utility of an abbreviated symptom score for the most pertinent and representative MPN symptoms for subsequent serial use in assessing response to therapy. Patients and Methods The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) was calculated as the mean score for 10 items from two previously validated scoring systems. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Results MPN-SAF TSS was calculable for 1,408 of 1,433 patients with MPNs who had a mean score of 21.2 (standard deviation [SD], 16.3). MPN-SAF TSS results significantly differed among MPN disease subtypes (P < .001), with a mean of 18.7 (SD, 15.3), 21.8 (SD, 16.3), and 25.3 (SD, 17.2) for patients with essential thrombocythemia, polycythemia vera, and myelofibrosis, respectively. The MPN-SAF TSS strongly correlated with overall quality of life (QOL; r = 0.59; P < .001) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) functional scales (all P < .001 and absolute r ≥ 0.50 except social functioning r = 0.48). No significant trends were present when comparing therapy subgroups. The MPN-SAF TSS had excellent internal consistency (Cronbach's α = .83). Factor analysis identified a single underlying construct, indicating that the MPN-SAF TSS is an appropriate, unified scoring method. Conclusion The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptom study to date. This new prospective scoring method may be used to assess MPN symptom burden in both clinical practice and trial settings.

Published
2012

6. Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia.

Author

Harrison, Claire N., primary, Egyed, Miklos, additional, Szoke, Anita, additional, Suvorov, Aleksandr, additional, Perkins, Andrew, additional, Mayer, Jiri, additional, Ganly, Peter, additional, Schouten, Harry C., additional, Tosi, Patrizia, additional, Farber, Charles Michael, additional, Zachee, Pierre, additional, Scheid, Christof, additional, Dean, James P., additional, Zhou, Huafeng, additional, Kiladjian, Jean-Jacques, additional, Vannucchi, Alessandro M., additional, Nangalia, Jyoti, additional, Mead, Adam, additional, and Mesa, Ruben A., additional

Published
2016
Full Text
View/download PDF

7. Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial.

Author

Mesa, Ruben A., primary, Egyed, Miklos, additional, Szoke, Anita, additional, Suvorov, Aleksandr, additional, Perkins, Andrew, additional, Mayer, Jiri, additional, Ganly, Peter, additional, Schouten, Harry C., additional, Tosi, Patrizia, additional, Farber, Charles Michael, additional, Zachee, Pierre, additional, Scheid, Christof, additional, Dean, James P., additional, Granston, Tanya, additional, Kiladjian, Jean-Jacques, additional, Vannucchi, Alessandro M., additional, Nangalia, Jyoti, additional, Mead, Adam, additional, and Harrison, Claire N., additional

Published
2016
Full Text
View/download PDF

8. Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy.

Author

Harrison, Claire N., primary, Egyed, Miklos, additional, Szoke, Anita, additional, Suvorov, Aleksandr, additional, Perkins, Andrew, additional, Mayer, Jiri, additional, Ganly, Peter, additional, Schouten, Harry C., additional, Tosi, Patrizia, additional, Farber, Charles Michael, additional, Zachee, Pierre, additional, Scheid, Christof, additional, Dean, James P., additional, Zhou, Huafeng, additional, Kiladjian, Jean-Jacques, additional, Vannucchi, Alessandro M., additional, Nangalia, Jyoti, additional, Mead, Adam, additional, and Mesa, Ruben A., additional

Published
2016
Full Text
View/download PDF

9. Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).

Author

Mesa, Ruben A., primary, Egyed, Miklos, additional, Szoke, Anita, additional, Suvorov, Aleksandr, additional, Perkins, Andrew, additional, Mayer, Jiri, additional, Ganly, Peter, additional, Jourdan, Eric, additional, Schouten, Harry C., additional, Tosi, Patrizia, additional, Farber, Charles Michael, additional, Zachee, Pierre, additional, Scheid, Christof, additional, Dean, James P., additional, Cernohous, Paul, additional, Nangalia, Jyoti, additional, Kiladjian, Jean-Jacques, additional, Vannucchi, Alessandro M., additional, Mead, Adam, additional, and Harrison, Claire N., additional

Published
2015
Full Text
View/download PDF

10. Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality

Author

Fenske, Timothy S., primary, Zhang, Mei-Jie, additional, Carreras, Jeanette, additional, Ayala, Ernesto, additional, Burns, Linda J., additional, Cashen, Amanda, additional, Costa, Luciano J., additional, Freytes, César O., additional, Gale, Robert P., additional, Hamadani, Mehdi, additional, Holmberg, Leona A., additional, Inwards, David J., additional, Lazarus, Hillard M., additional, Maziarz, Richard T., additional, Munker, Reinhold, additional, Perales, Miguel-Angel, additional, Rizzieri, David A., additional, Schouten, Harry C., additional, Smith, Sonali M., additional, Waller, Edmund K., additional, Wirk, Baldeep M., additional, Laport, Ginna G., additional, Maloney, David G., additional, Montoto, Silvia, additional, and Hari, Parameswaran N., additional

Published
2014
Full Text
View/download PDF

11. Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma

Author

Smith, Sonali M., primary, Burns, Linda J., additional, van Besien, Koen, additional, LeRademacher, Jennifer, additional, He, Wensheng, additional, Fenske, Timothy S., additional, Suzuki, Ritsuro, additional, Hsu, Jack W., additional, Schouten, Harry C., additional, Hale, Gregory A., additional, Holmberg, Leona A., additional, Sureda, Anna, additional, Freytes, Cesar O., additional, Maziarz, Richard Thomas, additional, Inwards, David J., additional, Gale, Robert Peter, additional, Gross, Thomas G., additional, Cairo, Mitchell S., additional, Costa, Luciano J., additional, Lazarus, Hillard M., additional, Wiernik, Peter H., additional, Maharaj, Dipnarine, additional, Laport, Ginna G., additional, Montoto, Silvia, additional, and Hari, Parameswaran N., additional

Published
2013
Full Text
View/download PDF

14. Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry

Author

van Kampen, Roel J.W., primary, Canals, Carmen, additional, Schouten, Harry C., additional, Nagler, Arnon, additional, Thomson, Kirsty J., additional, Vernant, Jean-Paul, additional, Buzyn, Agnes, additional, Boogaerts, Marc A., additional, Luan, Jian-Jian, additional, Maury, Sébastien, additional, Milpied, Noel J., additional, Jouet, Jean-Pierre, additional, Ossenkoppele, Gert J., additional, and Sureda, Anna, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results